Vaccines for children and adults with chronic lung disease: Efficacy against acute exacerbations

Expert Review of Respiratory Medicine

Volumn 8, Issue 1, 2014, Pages 43-55

  O'Grady, Kerry Ann F ^a,b   Chang, Anne B ^b,c,d   Grimwood, Keith ^a,d  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^c MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^d ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

acute respiratory exacerbations; chronic lung disease; prevention; vaccine efficacy; vaccines

Indexed keywords

INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE;

ADULT DISEASE; BORDETELLA PERTUSSIS; CHILDHOOD DISEASE; CHRONIC LUNG DISEASE; DISEASE EXACERBATION; DRUG EFFICACY; HAEMOPHILUS INFLUENZAE; HUMAN; HUMAN RHINOVIRUS; INFLUENZA A; INFLUENZA B; INFLUENZA C; LUNG FUNCTION; MORAXELLA CATARRHALIS; PSEUDOMONAS AERUGINOSA; QUALITY OF LIFE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

ADULT; BACTERIAL VACCINES; CHILD; CHRONIC DISEASE; HUMANS; INFLUENZA VACCINES; LUNG DISEASES; PNEUMOCOCCAL VACCINES; TREATMENT OUTCOME; VIRAL VACCINES;

EID: 84893064643     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2014.852960     Document Type: Review

References (178)

1. O'Grady KF, Grimwood K, Cripps AW. et al.: Does a 10-valent pneumococcal- Haemophilus influenzae protein D conjugate vaccine prevent respiratory exacerbations in children with recurrent protracted bacterial bronchitis, chronic suppurative lung disease and bronchiectasis: Protocol for a randomised controlled trial. Trials 14, 282 (2013).
2. Petsky HL, Cates CJ, Li A. et al.: Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and adults. Cochrane Database Syst. Rev. (4), CD006340 (2009).
3. Martinez-Garcia MA, Soler-Cataluna JJ, Perpina-Tordera M. et al.: Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 132(5), 1565-1572 (2007).
4. Kapur N, Masters IB, Chang AB. Exacerbations in noncystic fibrosis bronchiectasis: Clinical features and investigations. Respir. Med. 103(11), 1681-1687 (2009).
5. Jacobs SE, Lamson DM, St George K, Walsh TJ. Human rhinoviruses. Clin. Microbiol. Rev. 26(1), 135-162 (2013).
6. Meerhoff TJ, Houben ML, Coenjaerts FE. et al.: Detection of multiple respiratory pathogens during primary respiratory infection: Nasal swab versus nasopharyngeal aspirate using real-Time polymerase chain reaction. Eur. J. Clin. Microbiol. Infect. Dis. 29(4), 365-371 (2010).
7. Ruuskanen O, Waris M, Ramilo O. New aspects on human rhinovirus infections. Pediatr. Infect. Dis. J. 32(5), 553-555 (2013).
8. Murdoch DR, O'Brien KL, Scott JA. et al.: Breathing new life into pneumonia diagnostics. J. Clin. Microbiol. 47(11), 3405-3408 (2009).
9. Mallia P, Footitt J, Sotero R. et al.: Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial infection in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 186(11), 1117-1124 (2012).
10. Mallia P, Message SD, Gielen V. et al.: Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. Am. J. Respir. Crit. Care Med. 183(6), 734-742 (2011).
11. Molyneaux PL, Mallia P, Cox MJ. et al.: Outgrowth of the bacterial airway microbiome following rhinovirus exacerbation of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. doi:10.1164/rccm.201302-0341OC (2013) (Epub ahead of print).
12. Cesario TC. Viruses associated with pneumonia in adults. Clin. Infect. Dis. 55(1), 107-113 (2012).
13. Kuchar E, Miskiewicz K, Szenborn L. Respiratory complications in children hospitalized with varicella. Adv. Exp. Med. Biol. 788, 97-102 (2013).
14. Parsons HK, Dockrell DH. The burden of invasive pneumococcal disease and the potential for reduction by immunisation. Int. J. Antimicrob. Agents 19(2), 85 (2002).
15. Leach AJ, Boswell JB, Asche V. et al.: Bacterial colonization of the nasopharynx predicts very early onset and persistence of otitis media in Australian aboriginal infants. Pediatr. Infect. Dis. J. 13(11), 983-989 (1994).
16. Brueggemann AB, Peto TE, Crook DW. et al.: Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children. J. Infect. Dis. 190(7), 1203 (2004).
17. Jefferson T, Ferroni E, Curtale F. et al.: Streptococcus pneumoniae in western Europe: Serotype distribution and incidence in children less than 2 years old. Lancet Infect. Dis. 6(7), 405-410 (2006).
18. Brueggemann AB, Griffiths DT, Meats E. et al.: Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential. J. Infect. Dis. 187(9), 1424-1432 (2003).
19. Hare KM, Grimwood K, Leach AJ. et al.: Respiratory bacterial pathogens in the nasopharynx and lower airways of Australian indigenous children with bronchiectasis. J. Pediatr. 157(6), 1001-1005 (2010).
20. Kapur N, Grimwood K, Masters IB. et al.: Lower airway microbiology and cellularity in children with newly diagnosed non-CF bronchiectasis. Pediatr. Pulmonol. 47(3), 300-307 (2012).
21. Patel IS, Seemungal TA, Wilks M. et al.: Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 57(9), 759-764 (2002).
22. Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest 117(5 Suppl. 2), 380S-385S (2000).
23. Sethi S, Muscarella K, Evans N. et al.: Airway inflammation and etiology of acute exacerbations of chronic bronchitis. Chest 118(6), 1557-1565 (2000).
24. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N. Engl. J. Med. 359, 2355-2366 (2008).
25. Talbot TR, Hartert TV, Mitchel E. et al.: Asthma as a risk factor for invasive pneumococcal disease. N. Engl. J. Med. 352(20), 2082-2090 (2005).
26. Fletcher MA, Laufer DS, McIntosh ED. et al.: Controlling invasive pneumococcal disease: Is vaccination of at-risk groups sufficient? Int. J. Clin. Pract. 60(4), 450-456 (2006).
27. Fedson DS, Scott JA. The burden of pneumococcal disease among adults in developed and developing countries: What is and is not known. Vaccine 17(Suppl. 17), S11 (1999).
28. Juhn YJ, Kita H, Yawn BP. et al.: Increased risk of serious pneumococcal disease in patients with asthma. J. Allergy Clin. Immunol. 122(4), 719-723 (2008).
29. Alfageme I, Vazquez R, Reyes N. et al.: Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 61(3), 189-195 (2006).
30. Jackson LA, Neuzil KM, Yu O. et al.: Effectiveness of pneumococcal polysaccharide vaccine in older adults. N. Engl. J. Med. 348(18), 1747 (2003).
31. Moberley SA, Holden J, Tatham DP. et al.: Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst. Rev. (1), CD000422 (2008).
32. Watson L, Wilson BJ, Waugh N. Pneumococcal polysaccharide vaccine: A systematic review of clinical effectiveness in adults. Vaccine 20(17-18), 2166 (2002).
33. Chang CC, Singleton R, Morris P. et al.: Pneumococcal vaccines for children and adults with bronchiectasis. Cochrane Database Syst. Rev. (2), CD006316 (2009).
34. Varkey JB, Varkey AB, Varkey B: Prophylactic vaccinations in chronic obstructive pulmonary disease: Current status. Curr. Opin. Pulm. Med. 15(2), 90-99 (2009).
35. Obaro S, Leach A, McAdam KW. Use of pneumococcal polysaccharide vaccine in children. Lancet 352(9127), 575 (1998).
36. Overturf GD. American Academy of Pediatrics. Committee on infectious diseases. Technical report: Prevention of pneumococcal infections, including the use of pneumococcal conjugate and polysaccharide vaccines and antibiotic prophylaxis. Pediatrics 106(2 Pt 1), 367 (2000).
37. National Health & Medical Research Council. The Australian Immunisation Handbook (10th Edition). Australian Government, Canberra, Australia (2013).
38. Lehmann D. Pneumococcal polysaccharide vaccine prevents death from pneumonia in Papua New Guinean children. PNG Med. J. 29(4), 281-283 (1986).
39. Riley ID, Lehmann D, Alpers MP. Pneumococcal vaccine trials in Papua New Guinea: Relationships between epidemiology of pneumococcal infection and efficacy of vaccine. Rev. Infect. Dis. 13(Suppl. 13), 535-541 (1991).
40. Riley ID, Lehmann D, Alpers MP. et al.: Pneumococcal vaccine prevents death from acute lower-respiratory-Tract infections in Papua New Guinean children. Lancet 2(8512), 877-881 (1986).
41. Herva E, Luotonen J, Timonen M. et al.: The effect of polyvalent pneumococcal polysaccharide vaccine on nasopharyngeal and nasal carriage of Streptococcus pneumoniae. Scand. J. Infect. Dis. 12(2), 97-100 (1980).
42. Borrow R, Heath PT, Siegrist CA. Use of pneumococcal polysaccharide vaccine in children: What is the evidencé Curr. Opin. Infect. Dis. 25(3), 292-303 (2012).
43. Tan TQ. Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines. Clin. Microbiol. Rev. 25(3), 409-419 (2012).
44. Fitzwater SP, Chandran A, Santosham M. et al.: The worldwide impact of the seven-valent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 31(5), 501-508 (2012).
45. Gladstone RA, Jefferies JM, Faust SN, Clarke SC. Pneumococcal 13-valent conjugate vaccine for the prevention of invasive pneumococcal disease in children and adults. Expert Rev. Vaccines 11(8), 889-902 (2012).
46. Hammitt LL, Bruden DL, Butler JC. et al.: Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: An explanation of trends in invasive pneumococcal disease. J. Infect. Dis. 193(11), 1487-1494 (2006).
47. Scott JR, Millar EV, Lipsitch M. et al.: Impact of more than a decade of pneumococcal conjugate vaccine use on carriage and invasive potential in Native American communities. J. Infect. Dis. 205(2), 280-288 (2012).
48. Spijkerman J, Prevaes SM, van Gils EJ. et al.: Long-Term effects of pneumococcal conjugate vaccine on nasopharyngeal carriage of S. pneumoniae, S. aureus, H. influenzae and M. catarrhalis. PLoS ONE 7(6), e39730 (2012).
49. Griffin MR, Zhu Y, Moore MR. et al.: U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N. Engl. J. Med. 369(2), 155-163 (2013).
50. Burgess L, Southern KW. Pneumococcal vaccines for cystic fibrosis. Cochrane Database Syst. Rev. 9, CD008865 (2012).
51. Walters JA, Smith S, Poole P. et al.: Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. (11), CD001390 (2010).
52. Dransfield MT, Harnden S, Burton RL. et al.: Long-Term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. Clin. Infect. Dis. 55(5), e35-44 (2012).
53. Advani A, Hallander HO, Dalby T. et al.: Pulsed-field gel electrophoresis analysis of Bordetella pertussis isolates circulating in Europe from 1998 to 2009. J. Clin. Microbiol. 51(2), 422-428 (2013).
54. Cherry JD: Epidemiological, clinical, and laboratory aspects of pertussis in adults. Clin. Infect. Dis. 28(Suppl. 28), S112-117 (1999).
55. Amirthalingam G. Strategies to control pertussis in infants. Arch. Dis. Child 98(7), 552-555 (2013).
56. Mooi FR, NA VDM, De Melker HE. Pertussis resurgence: Waning immunity and pathogen adaptation-Two sides of the same coin. Epidemiol. Infect. 1-10 (2013).
57. Jackson DW, Rohani P. Perplexities of pertussis: Recent global epidemiological trends and their potential causes. Epidemiol. Infect. 1-13 (2013).
58. Sheridan SL, Ware RS, Grimwood K. et al.: Number and order of whole cell pertussis vaccines in infancy and disease protection. JAMA 308(5), 454-456 (2012).
59. Witt MA, Arias L, Katz PH. et al.: Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort. Clin. Infect. Dis. 56(9), 1248-1254 (2013).
60. Tartof SY, Lewis M, Kenyon C. et al.: Waning immunity to pertussis following 5 doses of DTaP. Pediatrics 131(4), e1047-1052 (2013).
61. Soane MC, Jackson A, Maskell D. et al.: Interaction of Bordetella pertussis with human respiratory mucosa in vitro. Respir. Med. 94(8), 791-799 (2000).
62. De Serres G, Shadmani R, Duval B. et al.: Morbidity of pertussis in adolescents and adults. J. Infect. Dis. 182(1), 174-179 (2000).
63. Capili CR, Hettinger A, Rigelman-Hedberg N. et al.: Increased risk of pertussis in patients with asthma. J. Allergy Clin. Immunol. 129(4), 957-963 (2012).
64. Harju TH, Leinonen M, Nokso-Koivisto J. et al.: Pathogenic bacteria and viruses in induced sputum or pharyngeal secretions of adults with stable asthma. Thorax 61(7), 579-584 (2006).
65. Bos AC, Beemsterboer P, Wolfs TF. et al.: Bordetella species in children with cystic fibrosis: What do we know? The role in acute exacerbations and chronic course. J. Cyst. Fibros. 10(5), 307-312 (2011).
66. Wright PF, Neumann G, Kawoaka Y. Orthomyxoviruses. In: Field's Virology. Volume 2, (5th Edition). Knipe DM (Ed.). Lippincott, Williams and Wilkins, Philadelphia, PA, USA, 1691-1740 (2007).
67. Steinhoff MC. Influenza in young children: Burden, immunisation, and policy. Lancet Infect. Dis. 11(1), 2-3 (2011).
68. Rivetti D, Jefferson T, Thomas R. et al.: Vaccines for preventing influenza in the elderly. Cochrane Database Syst. Rev. 3, CD004876 (2006).
69. Regan J, Fowlkes A, Biggerstaff M. et al.: Epidemiology of influenza A (H1N1) pdm09-Associated deaths in the United States, September-October 2009. Influenza Other Respi. Viruses 6(6), e169-177 (2012).
70. Tamma PD, Steinhoff MC, Omer SB. Influenza infection and vaccination in pregnant women. Expert Rev. Respir. Med. 4(3), 321-328 (2010).
71. Fraaij PL, Heikkinen T. Seasonal influenza: The burden of disease in children. Vaccine 29(43), 7524-7528 (2011).
72. Jang YH, Seong BL. Principles underlying rational design of live attenuated influenza vaccines. Clin. Exp. Vaccine Res. 1(1), 35-49 (2012).
73. Mohan A, Chandra S, Agarwal D. et al.: Prevalence of viral infection detected by PCR and RT-PCR in patients with acute exacerbation of COPD: A systematic review. Respirology 15(3), 536-542 (2010).
74. Mackay AJ, Hurst Jr. COPD exacerbations: Causes, prevention, and treatment. Immunol. Allergy Clin. North Am. 33(1), 95-115 (2013).
75. Wedzicha JA, Donaldson GC: Exacerbations of chronic obstructive pulmonary disease. Respir. Care 48(12), 1204-1213, discussion 1213-1205 (2003).
76. Plans-Rubio P. Prevention and control of influenza in persons with chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 2(1), 41-53 (2007).
77. Poole PJ, Chacko E, Wood-Baker RW. et al.: Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. (1), CD002733 (2006).
78. Cates CJ, Rowe BH. Vaccines for preventing influenza in people with asthma. Cochrane Database Syst. Rev. 2, CD000364 (2013).
79. Vesikari T. Emerging data on the safety and efficacy of influenza vaccines in children. Pediatr Infect. Dis. J. 27(11 Suppl.), S159-161 (2008).
80. Chang CC, Morris PS, Chang AB. Influenza vaccine for children and adults with bronchiectasis. Cochrane Database Syst. Rev. (3), CD006218 (2007).
81. Patria MF, Longhi B, Esposito S. Influenza vaccination in children with cystic fibrosis. Expert Rev. Vaccines 12(4), 415-420 (2013).
82. Dharmaraj P, Smyth RL. Vaccines for preventing influenza in people with cystic fibrosis. Cochrane Database Syst. Rev. (4), CD001753 (2009).
83. Doshi P. Influenza: Marketing vaccine by marketing disease. BMJ 346, f3037 (2013).
84. Osterholm MT, Kelley NS, Sommer A. et al.: Efficacy and effectiveness of influenza vaccines: A systematic review and meta-Analysis. Lancet Infect. Dis. 12(1), 36-44 (2012).
85. McCullers JA. Insights into the interaction between influenza virus and pneumococcus. Clin. Microbiol. Rev. 19(3), 571-582 (2006).
86. McCullers JA, Rehg JE. Lethal synergism between influenza virus and Streptococcus pneumoniae: Characterization of a mouse model and the role of platelet-Activating factor receptor. J. Infect. Dis. 186(3), 341-350 (2002).
87. Madhi SA, Klugman KP. A role for Streptococcus pneumoniae in virus-Associated pneumonia. Nat. Med. 10(8), 811-813 (2004).
88. Hament JM, Kimpen JL, Fleer A. et al.: Respiratory viral infection predisposing for bacterial disease: A concise review. FEMS Immunol. Med. Microbiol. 26(3-4), 189-195 (1999).
89. Peltola VT, McCullers JA. Respiratory viruses predisposing to bacterial infections: Role of neuraminidase. Pediatr Infect. Dis. J. 23(1 Suppl.), S87-97 (2004).
90. Nokso-Koivisto J, Pyles RB, Miller AL. et al.: Viral load and acute otitis media development after human metapneumovirus upper respiratory tract infection. Pediatr Infect. Dis. J. 31(7), 763-766 (2012).
91. Ruohola A, Pettigrew MM, Lindholm L. et al.: Bacterial and viral interactions within the nasopharynx contribute to the risk of acute otitis media. J. Infect. 66(3), 247-254 (2013).
92. Omer SB, Zaman K, Roy E. et al.: Combined effects of antenatal receipt of influenza vaccine by mothers and pneumococcal conjugate vaccine receipt by infants: Results from a randomized, blinded, controlled trial. J. Infect. Dis. 207(7), 1144-1147 (2013).
93. Nichol KL. The additive benefits of influenza and pneumococcal vaccinations during influenza seasons among elderly persons with chronic lung disease. Vaccine 17(Suppl. 17), S91-93 (1999).
94. Sumitani M, Tochino Y, Kamimori T. et al.: Additive inoculation of influenza vaccine and 23-valent pneumococcal polysaccharide vaccine to prevent lower respiratory tract infections in chronic respiratory disease patients. Intern. Med. 47(13), 1189-1197 (2008).
95. Furumoto A, Ohkusa Y, Chen M. et al.: Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine 26(33), 4284-4289 (2008).
96. Plotkin SA. A short history of vaccination. In: Vaccines (4th Edition). Plotkin SA, Orenstein WA, Offit PA (Eds). Saunders, Philadelphia, PA, USA (2004).
97. Tristram S, Jacobs MR, Appelbaum PC. Antimicrobial resistance in Haemophilus influenzae. Clin. Microbiol. Rev. 20(2), 368-389 (2007).
98. Agrawal A, Murphy TF. Haemophilus influenzae infections in the H. influenzae type b conjugate vaccine era. J. Clin. Microbiol. 49(11), 3728-3732 (2011).
99. Gkentzi D, Slack MP, Ladhani SN. The burden of nonencapsulated Haemophilus influenzae in children and potential for prevention. Curr. Opin. Infect. Dis. 25(3), 266-272 (2012).
100. Watt JP, Wolfson LJ, O'Brien KL. et al.: Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: Global estimates. Lancet 374(9693), 903-911 (2009).
101. Lutwick L, Fernandes L. The other siblings: Respiratory infections caused by Moraxella catarrhalis and Haemophilus influenzae. Curr. Infect. Dis. Rep. 8(3), 215-221 (2006).
102. Zaid AA, Elnazir B, Greally P: A decade of non-cystic fibrosis bronchiectasis 1996-2006. Ir. Med. J. 103(3), 77-79 (2010).
103. Banjar HH. A review of 151 cases of pediatric noncystic fibrosis bronchiectasis in a tertiary care center. Ann. Thorac. Med. 2(1), 3-8 (2007).
104. Karadag B, Karakoc F, Ersu R. et al.: Non-cystic-fibrosis bronchiectasis in children: A persisting problem in developing countries. Respiration 72(3), 233-238 (2005).
105. Munro KA, Reed PW, Joyce H. et al.: Do New Zealand children with non-cystic fibrosis bronchiectasis show disease progressioñ Pediatr. Pulmonol. 46(2), 131-138 2010.
106. Grimwood K. Airway microbiology and host defences in paediatric non-CF bronchiectasis. Paediatr. Respir. Rev. 12(2), 111-118 (2011).
107. Wainwright CE, Vidmar S, Armstrong DS. et al.: Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: A randomized trial. JAMA 306(2), 163-171 (2011).
108. Vandenbranden SL, McMullen A, Schechter MS. et al.: Lung function decline from adolescence to young adulthood in cystic fibrosis. Pediatr. Pulmonol. 47(2), 135-143 (2012).
109. Bandi V, Apicella MA, Mason E. Nontypeable Haemophilus influenzae in the lower respiratory tract of patients with chronic bronchitis. Am. J. Respir. Crit. Care Med. 164(11), 2114-2119 (2001).
110. Hill AT, Campbell EJ, Hill SL. et al.: Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am. J. Med. 109(4), 288-295 (2000).
111. Clancy R, Cripps A, Murree-Allen K. et al.: Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease. Lancet 2(8469-8470), 1395-1397 (1985).
112. Foxwell AR, Cripps AW, Dear KB. Haemophilus influenzae oral whole cell vaccination for preventing acute exacerbations of chronic bronchitis. Cochrane Database Syst. Rev. (4), CD001958 (2006).
113. Lehmann D, Coakley KJ, Coakley CA. et al.: Reduction in the incidence of acute bronchitis by an oral Haemophilus influenzae vaccine in patients with chronic bronchitis in the highlands of Papua New Guinea. Am. Rev. Respir. Dis. 144(2), 324-330 (1991).
114. Tandon MK, Phillips M, Waterer G. et al.: Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD. Chest 137(4), 805-811 (2010).
115. Wallace FJ, Cripps AW, Clancy RL et al.: A role for intestinal T lymphocytes in bronchus mucosal immunity Immunology 74(1), 68-73 (1991).
116. Forsgren A, Riesbeck K, Janson H. Protein D of Haemophilus influenzae: A protective nontypeable H. influenzae antigen and a carrier for pneumococcal conjugate vaccines. Clin. Infect. Dis. 46(5), 726-731 (2008).
117. Prymula R, Chlibek R, Splino M. et al.: Safety of the 11-valent pneumococcal vaccine conjugated to non-Typeable Haemophilus influenzae-derived protein D in the first 2 years of life and immunogenicity of the co-Administered hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio virus, Haemophilus influenzae type b and control hepatitis A vaccines. Vaccine 26(35), 4563-4570 (2008).
118. Prymula R, Kriz P, Kaliskova E. et al.: Effect of vaccination with pneumococcal capsular polysaccharides conjugated to Haemophilus influenzae-derived protein D on nasopharyngeal carriage of Streptococcus pneumoniae and H. influenzae in children under 2 years of age. Vaccine 28(1), 71-78 (2009).
119. Prymula R, Peeters P, Chrobok V. et al.: Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-Typable Haemophilus influenzae: A randomised double-blind efficacy study. Lancet 367(9512), 740-748 (2006).
120. Sa'ez-Llorens X, D. Wong, M. Rodri'guez. Impact of 10-valent pneumococcal non-Typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) nasopharyngeal bacterial carriage in Panamanian children. Presented at: 29th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID). The Hague, The Netherlands, 16-19 November 2011.
121. Sa'ez-Llorens X. Efficacy of 10-valent pneumococcal non-Typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) against acute otitis media in children in Panama. Presented at: 9th International Symposium on Antimicrobial Agents and Resistance (ISAAR). Kuala Lumpur, Malaysia, 13-15 March 2013.
122. van den Bergh MR, Spijkerman J, Swinnen KM. et al.: Effects of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine on nasopharyngeal bacterial colonization in young children: A randomized controlled trial. Clin. Infect. Dis. 56(3), e30-e39 (2013).
123. Novotny LA, Clements JD, Bakaletz LO. Kinetic analysis and evaluation of the mechanisms involved in the resolution of experimental nontypeable Haemophilus influenzae-induced otitis media after transcutaneous immunization. Vaccine 31(34), 3417-3426 (2013).
124. Bakaletz LO. Bacterial biofilms in the upper airway-evidence for role in pathology and implications for treatment of otitis media. Paediatr. Respir. Rev. 13(3), 154-159 (2012).
125. Sethi S, Wrona C, Eschberger K. et al.: Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 177, 491-497 (2008).
126. Murphy TF, Parameswaran GI. Moraxella catarrhalis, a human respiratory tract pathogen. Clin. Infect. Dis. 49(1), 124-131 (2009).
127. Mawas F, Ho MM, Corbel MJ. Current progress with Moraxella catarrhalis antigens as vaccine candidates. Expert Rev. Vaccines 8(1), 77-90 (2009).
128. Smidt M, Battig P, Verhaegh SJ. et al.: Comprehensive Antigen Screening Identifies Moraxella catarrhalis Proteins That Induce Protection in a Mouse Pulmonary Clearance Model. PLoS ONE 8(5), e64422 (2013).
129. Ruckdeschel EA, Brauer AL, Johnson A. Characterization of proteins Msp22 and Msp75 as vaccine antigens of Moraxella catarrhalis. Vaccine 27(50), 7065-7072 (2009).
130. Yang M, Johnson A, Murphy TF. Characterization and evaluation of the Moraxella catarrhalis oligopeptide permease A as a mucosal vaccine antigen. Infect. Immun. 79(2), 846-857 (2011).
131. Thwaites GE, Edgeworth JD, Gkrania-Klotsas E. et al.: Clinical management of Staphylococcus aureus bacteraemia. Lancet Infect. Dis. 11(3), 208-222 (2011).
132. Dasenbrook EC, Merlo CA, Diener-West M. et al.: Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am. J. Respir. Crit. Care Med. 178(8), 814-821 (2008).
133. Kahl BC. Impact of Staphylococcus aureus on the pathogenesis of chronic cystic fibrosis lung disease. Int. J. Med. Microbiol. 300(8), 514-519 (2010).
134. De Serres G, Lampron N, La Forge J. et al.: Importance of viral and bacterial infections in chronic obstructive pulmonary disease exacerbations. J. Clin. Virol. 46(2), 129-133 (2009).
135. Lin SH, Kuo PH, Hsueh PR. et al.: Sputum bacteriology in hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease in Taiwan with an emphasis on Klebsiella pneumoniae and Pseudomonas aeruginosa. Respirology 12(1), 81-87 (2007).
136. King PT, Holdsworth SR, Freezer NJ. et al.: Microbiologic follow-up study in adult bronchiectasis. Respir. Med. 101(8), 1633-1638 (2007).
137. Gregerson A, Daum RS. Staphylococcus aureus vaccine. In: Vaccines (4th Edition). Plotkin SA, Orenstein W (Eds). Elsevier Inc., Philadelphia, PA, 1347-1355 (2004).
138. Proctor RA. Challenges for a universal Staphylococcus aureus vaccine. Clin. Infect. Dis. 54(8), 1179-1186 (2012).
139. Pier G. Will there ever be a universal Staphylococcus aureus vacciné Hum. Vaccin. Immunother. 9(9), (2013).
140. Proctor RA Is there a future for a Staphylococcus aureus vacciné Vaccine 30(19), 2921-2927 (2012).
141. Wertheim HF, Melles DC, Vos MC. et al.: The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect. Dis. 5(12), 751-762 (2005).
142. Joshi A, Pancari G, Cope L. et al.: Immunization with Staphylococcus aureus iron regulated surface determinant B (IsdB) confers protection via Th17/IL17 pathway in a murine sepsis model. Hum. Vaccin. Immunother. 8(3), 336-346 (2012).
143. Valderrey AD, Pozuelo MJ, Jimenez PA. et al.: Chronic colonization by Pseudomonas aeruginosa of patients with obstructive lung diseases: Cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary disease. Diagn. Microbiol. Infect. Dis. 68(1), 20-27 (2010).
144. Parameswaran GI, Sethi S. Pseudomonas infection in chronic obstructive pulmonary disease. Future Microbiol. 7(10), 1129-1132 (2012).
145. Hauser AR, Jain M, Bar-Meir M. et al.: Clinical significance of microbial infection and adaptation in cystic fibrosis. Clin. Microbiol. Rev. 24(1), 29-70 (2011).
146. Johansen HK, Gotzsche PC. Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst. Rev. 6, CD001399 (2013).
147. Lang A. Clinical Trial Protocol No. KV9909. Double-Blind, Randomised, Placebo Controlled, Multi-Centre trial to Determine the Efficacy of Aerugen Berna Vaccine to Prevent Respiratory Tract Infections with P. aeruginosa in Non-Colonised Patients with Cystic Fibrosis. Swiss Serum and Vaccine Institute, Bern, Switzerland (2000).
148. Doring G, Meisner C, Stern M. et al.: A double-blind randomized placebo-controlled Phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. Proc. Natl Acad. Sci. USA 104(26), 11020-11025 (2007).
149. Langford DT, Hiller J. Prospective, controlled study of a polyvalent pseudomonas vaccine in cystic fibrosis-Three year results. Arch. Dis. Child 59(12), 1131-1134 (1984).
150. Wu W, Huang J, Duan B. et al.: Th17-stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia. Am. J. Respir. Crit. Care Med. 186(5), 420-427 (2012).
151. Doring G. Vaccine development for patients with cystic fibrosis. Expert Rev. Vaccines 11(3), 259-261 (2012).
152. Collins PL, Crowe JE. Respiratory syncytial virus and metapneumovirus. In: Field's Virology. Volume 2 (5th Edition). Knipe DM (Ed.). Lippincott, Williams and Wilkins, Philadelphia, PA, 1601-1646 (2007).
153. Hall CB. The burgeoning burden of respiratory syncytial virus among children. Infect. Disord. Drug Targets 12(2), 92-97 (2012).
154. Hardelid P, Pebody R, Andrews N. Mortality caused by influenza and respiratory syncytial virus by age group in England and Wales 1999-2010. Influenza Other Respir. Viruses 7(1), 35-45 (2013).
155. Widmer K, Zhu Y, Williams JV. et al.: Rates of hospitalizations for respiratory syncytial virus, human metapneumovirus, and influenza virus in older adults. J. Infect. Dis. 206(1), 56-62 (2012).
156. Nair H, Nokes DJ, Gessner BD. et al.: Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: A systematic review and meta-Analysis. Lancet 375(9725), 1545-1555 (2010).
157. Mehta J, Walsh EE, Mahadevia PJ, Falsey AR. Risk factors for respiratory syncytial virus illness among patients with chronic obstructive pulmonary disease. COPD 10(3), 293-299 (2013).
158. Piedimonte G. Respiratory syncytial virus and asthma: Speed-dating or long-Term relationship? Curr. Opin. Pediatr. 25(3), 344-349 (2013).
159. Anderson LJ. Respiratory syncytial virus vaccine development. Semin. Immunol. 25(2), 160-171 (2013).
160. Karron RA. Respiratory Syncytial Virus Vaccine. In: Vaccines (4th Edition) Plotkin SA, Orenstein W (Eds). Elsevier, Philadelphia, PA (2004).
161. Hurwitz JL. Respiratory syncytial virus vaccine development. Expert Rev. Vaccines 10(10), 1415-1433 (2011).
162. McIntyre CL, Knowles NJ, Simmonds P. Proposals for the classification of human rhinovirus species A, B and C into genotypically assigned types. J. Gen. Virol. 94(Pt 8), 1791-1806 (2013).
163. Johnston SL, Pattemore PK, Sanderson G. et al.: Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ 310(6989), 1225-1229 (1995).
164. Nicholson KG, Kent J, Ireland DC. Respiratory viruses and exacerbations of asthma in adults. BMJ 307(6910), 982-986 (1993).
165. Xepapadaki P, Papadopoulos NG. Childhood asthma and infection: Virus-induced exacerbations as determinants and modifiers. Eur. Respir. J. 36(2), 438-445 (2010).
166. Seemungal T, Harper-Owen R, Bhowmik A. et al.: Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 164(9), 1618-1623 (2001).
167. Papi A, Contoli M. Rhinovirus vaccination: The case against. Eur. Respir. J. 37(1), 5-7 (2011).
168. Rohde GG. Rhinovirus vaccination: The case in favour. Eur. Respir. J. 37(1), 3-4 (2011).
169. Edlmayr J, Niespodziana K, Popow-Kraupp T. et al.: Antibodies induced with recombinant VP1 from human rhinovirus exhibit cross-neutralisation. Eur. Respir. J. 37(1), 44-52 (2011).
170. Rossmann MG, Arnold E, Erickson JW. et al.: Structure of a human common cold virus and functional relationship to other picornaviruses. Nature 317(6033), 145-153 (1985).
171. Australian Institute of Health & Welfare. Vaccination Uptake Among People with Chronic Lung Disease. Cat # ACM25. Australian Government, Canberra, Australia (2012).
172. Loerbroks A, Stock C, Bosch JA. et al.: Influenza vaccination coverage among high-risk groups in 11 European countries. Eur. J. Public Health 22(4), 562-568 (2012).
173. Perez X, Wisnivesky JP, Lurslurchachai L. et al.: Barriers to adherence to COPD guidelines among primary care providers. Respir. Med. 106(3), 374-381 (2012).
174. Santos-Sancho JM, Jimenez-Trujillo I, Hernandez-Barrera V. et al.: Influenza vaccination coverage and uptake predictors among Spanish adults suffering COPD. Hum. Vaccin. Immunother. 8(7), 938-945 (2012).
175. Dickson RP, Erb-Downward JR, Huffnagle GB. The role of the bacterial microbiome in lung disease. Expert Rev. Respir. Med. 7(3), 245-257 (2013).
176. Fox CB, Haensler J. An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants. Expert Rev. Vaccines 12(7), 747-758 (2013).
177. Monto AS. Seasonal influenza vaccinations: Specialized products for different target groups. Vaccine 28(Suppl. 28), D14-23 (2010).
178. Matsuo K, Hirobe S, Okada N. et al.: Frontiers of transcutaneous vaccination systems: Novel technologies and devices for vaccine delivery. Vaccine 31(19), 2403-2415 (2013).